BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28341730)

  • 1. Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant
    Deng AL; Kim YR; Lichtenstein EA; O'Connor OA; Deng C
    Haematologica; 2017 Jul; 102(7):e275-e277. PubMed ID: 28341730
    [No Abstract]   [Full Text] [Related]  

  • 2. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
    Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
    Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.
    Kersten MJ; Kraan W; Doorduijn J; Bromberg J; Lam K; Kluin PM; van der Holt BJ; Spaargaren M; Pals ST
    Blood Cancer J; 2014 Dec; 4(12):e266. PubMed ID: 25501023
    [No Abstract]   [Full Text] [Related]  

  • 4. High prevalence of
    Schrader AMR; Jansen PM; Willemze R; Vermeer MH; Cleton-Jansen AM; Somers SF; Veelken H; van Eijk R; Kraan W; Kersten MJ; van den Brand M; Stevens WBC; de Jong D; Abdul Hamid M; Tanis BC; Posthuma EFM; Nijland M; Diepstra A; Pals ST; Cleven AHG; Vermaat JSP
    Blood; 2018 May; 131(18):2086-2089. PubMed ID: 29514783
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
    Wilson WH; Young RM; Schmitz R; Yang Y; Pittaluga S; Wright G; Lih CJ; Williams PM; Shaffer AL; Gerecitano J; de Vos S; Goy A; Kenkre VP; Barr PM; Blum KA; Shustov A; Advani R; Fowler NH; Vose JM; Elstrom RL; Habermann TM; Barrientos JC; McGreivy J; Fardis M; Chang BY; Clow F; Munneke B; Moussa D; Beaupre DM; Staudt LM
    Nat Med; 2015 Aug; 21(8):922-6. PubMed ID: 26193343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.
    Kraan W; van Keimpema M; Horlings HM; Schilder-Tol EJ; Oud ME; Noorduyn LA; Kluin PM; Kersten MJ; Spaargaren M; Pals ST
    Leukemia; 2014 Mar; 28(3):719-20. PubMed ID: 24253023
    [No Abstract]   [Full Text] [Related]  

  • 7. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.
    Mondello P; Brea EJ; De Stanchina E; Toska E; Chang AY; Fennell M; Seshan V; Garippa R; Scheinberg DA; Baselga J; Wendel HG; Younes A
    JCI Insight; 2017 Mar; 2(6):e90196. PubMed ID: 28352655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.
    Frick M; Bettstetter M; Bertz S; Schwarz-Furlan S; Hartmann A; Richter T; Lenze D; Hummel M; Dreyling M; Lenz G; Gaumann A
    Leuk Lymphoma; 2018 May; 59(5):1260-1263. PubMed ID: 28868954
    [No Abstract]   [Full Text] [Related]  

  • 9. [Combination of zanubrutinib and rituximab in the treatment of primary cutaneous diffuse large B-cell lymphoma leg type with CD79B and MYD88 mutations: a case report].
    Zhong GC; Yu XN; Li J; Chen CY
    Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):258. PubMed ID: 37356991
    [No Abstract]   [Full Text] [Related]  

  • 10. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
    Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
    Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
    Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S
    Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.
    Ducharme O; Beylot-Barry M; Pham-Ledard A; Bohers E; Viailly PJ; Bandres T; Faur N; Frison E; Vergier B; Jardin F; Merlio JP; Gros A
    J Invest Dermatol; 2019 Nov; 139(11):2334-2342.e8. PubMed ID: 31150604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Alterations and MYD88
    Jiang S; Qin Y; Gui L; Liu P; Jiang H; Liu B; Yang J; Yang S; He X; Zhou S; Du X; Yi Y; Lin J; Shi Y
    Target Oncol; 2020 Apr; 15(2):221-230. PubMed ID: 32239385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.
    Fox LC; Yannakou CK; Ryland G; Lade S; Dickinson M; Campbell BA; Prince HM
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29899297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nomogram for predicting survival of patients with diffuse large B-cell lymphoma.
    Fujii K; Inagaki A; Masaki A; Sugiura M; Suzuki T; Ishida T; Kusumoto S; Iida S; Inagaki H
    Ann Hematol; 2024 Jun; 103(6):2041-2050. PubMed ID: 38411628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
    Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC
    Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
    Yamada S; Ishida Y; Matsuno A; Yamazaki K
    Leuk Lymphoma; 2015 Jul; 56(7):2141-5. PubMed ID: 25347427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review.
    Xu PP; Shen R; Shi ZY; Cheng S; Wang L; Liu Y; Zhang L; Huang R; Ma X; Wu X; Yao H; Yu Y; Zhao WL
    Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1051-e1058.e1. PubMed ID: 36182550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of temozolomide instead of cyclophosphamide in diffuse large B-cell lymphoma.
    Cassou-Mounat T; Delwail V; Cayssials E; Terroir M; Puyade M
    Leuk Lymphoma; 2016; 57(3):724-5. PubMed ID: 26148876
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.